Andere talen Aura Biosciences, Inc.

Aandelen

AURA

US05153U1079

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,65 ^USD	+3,38%		+7,75%	-13,66%

15/04	Raj Parekh treedt af als lid van de raad van bestuur van Aura Biosciences, Inc. met ingang van 20 juni 2024	CI
27/03	Aandelen Aura Biosciences stijgen na Q4-resultaten	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	15/04
Aura Biosciences Shares Rise Following Q4 Results	27/03
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/03
Aura Biosciences to Participate in Upcoming Investor Conferences	26/02
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma	08/12
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	08/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16/11
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	09/11
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	09/11
Aura Biosciences to Participate in Upcoming Investor Conferences	08/11
Aura Biosciences Announces Pricing of Public Offering of Common Stock	07/11
Aura Biosciences Announces Proposed Public Offering of Common Stock	06/11
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma	06/11
Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar	06/11
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma	06/11
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma	01/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aura Biosciences, Inc.

Aandelen

AURA

US05153U1079

Andere talen

Filters